Replies to post #86352 on Biotech Values

[genisi]

From the PR it looks like the European trial didn't hit its primary endpoint rather a trend was seen: "A numerical increase in the number of SSEs compared to placebo supports the efficacy of flibanserin in pre-menopausal women suffering with HSDD." Also "about 14% and 16% of women on flibanserin 100mg and 8% and 5% of women on placebo discontinuing treatment due to AEs in the respective trials" (American and European). Seems high.